Trial Profile
A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose and Dose Regimen-Ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients With Active Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms EMBLEM
- Sponsors UCB
- 04 Jun 2014 Results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.
- 30 Oct 2013 Quality-of-life results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 09 Sep 2011 Additional location added as reported by ClinicalTrials.gov.